Innovus Pharma Expands its OTC Drug Pipeline with the Addition of OmepraCare™ (a Competitor of Prilosec® OTC)
InnovAge Holding Corp. (INNV)
NASDAQ:AMEX Investor Relations:
innovuspharma.com
Company Research
Source: Business Wire
This New Drug OmepraCare™ is Indicated for the Treatment of Frequent Heartburn and is Expected to add Significant Revenue to the Company SAN DIEGO--(BUSINESS WIRE)-- Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the “Company”) (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women's health and respiratory diseases, today announced that it has entered into a supply relationship with a third party to supply Innovus Pharma with omeprazole 20mg tablets and omeprazole 20mg 24 hour delayed release capsules indicated for the treatment of frequent heartburn under the approved abbreviated new drug application (“ANDA”) No. 207891 from the U.S. Food and Drug Administration (“FDA”). Innovus Pharma will launch the drug under its own trademark OmepraCare™ 20mg tab
Show less
Read more
Impact Snapshot
Event Time:
INNV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INNV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INNV alerts
High impacting InnovAge Holding Corp. news events
Weekly update
A roundup of the hottest topics
INNV
News
- InnovAge (NASDAQ:INNV) had its price target raised by analysts at JPMorgan Chase & Co. from $5.00 to $7.00. They now have an "underweight" rating on the stock.MarketBeat
- InnovAge (NASDAQ:INNV) was upgraded by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a> from a "sell (d-)" rating to a "hold (c-)" rating.MarketBeat
- InnovAge (NASDAQ:INNV) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.MarketBeat
- Assessing InnovAge Holding (INNV) Valuation After Recent Share Price Volatility [Yahoo! Finance]Yahoo! Finance
- Proven Senior Care Model Takes Center Stage at the CapitolGlobeNewswire
INNV
Earnings
- 2/3/26 - Beat
INNV
Analyst Actions
- 2/23/26 - JP Morgan
INNV
Sec Filings
- 2/3/26 - Form 10-Q
- 2/3/26 - Form 8-K
- 1/30/26 - Form 3
- INNV's page on the SEC website